NCT06215300

Brief Summary

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2022

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2022

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

January 8, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 22, 2024

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2025

Completed
Last Updated

January 22, 2024

Status Verified

January 1, 2024

Enrollment Period

2.9 years

First QC Date

January 8, 2024

Last Update Submit

January 10, 2024

Conditions

to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting

Keywords

cardiovascular system, coronary artery bypass grafting, aspirin resistance, GUCY1A3 gene polymorphism rs7692387, soluble guanylate cyclase (rGC)

Outcome Measures

Primary Outcomes (1)

  • myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

    myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

    12 months

Study Arms (2)

genotype GG

GG

Genetic: coronary artery bypass grafting

genotype AG/АА

AG/АА

Genetic: coronary artery bypass grafting

Interventions

coronary artery bypass graftingGENETIC

coronary artery bypass grafting

genotype AG/ААgenotype GG

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with IHD

You may qualify if:

  • Stable ischemic disease 2- 4
  • CABG

You may not qualify if:

  • the need to take any anticoagulants
  • thrombocytopenia
  • allergy to aspirin.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Novosibirsk research institute of circulation pathology

Novosibirsk, Novosibirsk Oblast, 630055, Russia

RECRUITING

Aleksey

Novosibirsk, Russia

RECRUITING

MeSH Terms

Interventions

Coronary Artery Bypass

Intervention Hierarchy (Ancestors)

Myocardial RevascularizationCardiac Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeVascular GraftingVascular Surgical ProceduresThoracic Surgical Procedures

Central Study Contacts

Aleksey Kurguzov, MD

CONTACT

+79137011917aleksey_kurguzov@mail.ru

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 8, 2024

First Posted

January 22, 2024

Study Start

December 1, 2022

Primary Completion

November 1, 2025

Study Completion

November 1, 2025

Last Updated

January 22, 2024

Record last verified: 2024-01

Locations

RU(2)